Interaction Checker

Interaksi Dasatinib

Dasatinib (Sprycel, Phyrago) memiliki 152 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 69 mayor, 30 moderat, 53 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (69)

  • AmiodaronantiaritmiaMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Antasida (Tums, Maalox, Mylanta)Produk obat bebasMayor

    Antacids: Avoid concomitant use. (label Dasatinib, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Mayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • AtazanavirantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Mayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • DarunavirantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • DronedaronantiaritmiaMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • EfavirenzantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Eritromisinantibiotik makrolidaMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • EtravirinantiretroviralMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • EverolimusimunosupresanMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • FenitoinantikonvulsanMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • FenobarbitalbarbituratMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Flukonazolantijamur azolMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • FosamprenavirantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Mayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • GriseofulvinantijamurMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Ibuprofen dan famotidinOAINSMayor

    Intervention Concomitant administration of ibuprofen and famotidine tablet is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. (label Ibuprofen dan famotidin, Interaksi obat)

  • Imatinibpenghambat CYP3A4Mayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • IsoniazidantibiotikMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Itrakonazolantijamur azolMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Mayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Ketokonazolantijamur azolMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Klaritromisinantibiotik makrolidaMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • KlobazambenzodiazepinMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • LenakapavirantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Mayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Mirabegronagonis beta-adrenergikMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Modafinilstimulan SSPMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Natrium bikarbonatantasidaMayor

    Antacids: Avoid concomitant use. (label Dasatinib, Interaksi obat)

  • NefazodonantidepresanMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • NevirapinantiretroviralMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonMayor

    Antacids: Avoid concomitant use. (label Dasatinib, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Mayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • PerampanelantikonvulsanMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Posakonazolantijamur azolMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • PrimidonantikonvulsanMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • RifabutinantibiotikMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • RifampisinantibiotikMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • RifapentinantibiotikMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • RitonavirantiretroviralMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • SenobamatantikonvulsanMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • SiklosporinimunosupresanMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Suvoreksantsedatif-hipnotikMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Mayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • TikagrelorantiplateletMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • TopiramatantikonvulsanMayor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (label Dasatinib, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

  • Vorikonazolantijamur azolMayor

    Avoid concomitant use of strong CYP3A4 inhibitors. (label Dasatinib, Interaksi obat)

Interaksi moderat (30)

  • AdenosinantiaritmiaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • ApiksabanantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

  • ArgatrobanantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

  • BivalirudinantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

  • DabigatranantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

  • Dekslansoprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Dekslansoprazol, Interaksi obat)

  • Digoksinglikosida digitalisModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • DisopiramidantiaritmiaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • DofetilidantiaritmiaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • EdoksabanantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

  • EnoksaparinantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

  • Esmololpenyekat betaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • Esomeprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole… (label Esomeprazol, Interaksi obat)

  • FlekainidantiaritmiaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • FondaparinuksantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

  • HeparinantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

  • IbutilidantiaritmiaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • KuinidinantiaritmiaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • Lansoprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Lansoprazol, Interaksi obat)

  • Lidokainanestetik lokalModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • Lidokain dan prilokainanestetik lokalModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • MeksiletinantiaritmiaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • Omeprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Omeprazol, Interaksi obat)

  • Pantoprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Pantoprazol, Interaksi obat)

  • ProkainamidantiaritmiaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • PropafenonantiaritmiaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • Rabeprazolpenghambat pompa protonModerat

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (label Rabeprazol, Interaksi obat)

  • RivaroksabanantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

  • Sotalolpenyekat betaModerat

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (label Dasatinib, Peringatan dan perhatian)

  • WarfarinantikoagulanModerat

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (label Dasatinib, Peringatan dan perhatian)

Penyebutan minor (53)

  • Amiloriddiuretik hemat kaliumMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Asetazolamidpenghambat karbonat anhidraseMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Atenolol dan klortalidonpenyekat betaMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Azelastin dan flutikasonantihistaminMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • BeklometasonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Benazepril dan hidroklorotiazidpenghambat ACEMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • BetametasonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Bisoprolol dan hidroklorotiazidpenyekat betaMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • BudesonidkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Bumetaniddiuretik loopMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • DeflazakortkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • DesonidkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Enalapril dan hidroklorotiazidpenghambat ACEMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Eplerenonantagonis aldosteronMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • FludrokortisonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • FlunisolidkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • FluosinonidkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • FlutikasonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Fosinopril dan hidroklorotiazidpenghambat ACEMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Furosemiddiuretik loopMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • HalobetasolkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Hidroklorotiaziddiuretik tiazidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • HidrokortisonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • KlobetasolkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Klorotiaziddiuretik tiazidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Kuinapril dan hidroklorotiazidpenghambat ACEMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Lisinopril dan hidroklorotiazidpenghambat ACEMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • MetilprednisolonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Metolazondiuretik tiazidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Metoprolol dan hidroklorotiazidpenyekat betaMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • MometasonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • PrednisolonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • PrednisonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • SiklesonidkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Torasemiddiuretik loopMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • TriamsinolonkortikosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

Periksa Dasatinib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.